{"id":520937,"date":"2021-07-30T19:26:50","date_gmt":"2021-07-30T23:26:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/"},"modified":"2021-07-30T19:26:50","modified_gmt":"2021-07-30T23:26:50","slug":"acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/","title":{"rendered":"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm"},"content":{"rendered":"
\n

\n Investors with losses are encouraged to contact the firm before <\/em>
\n August 9, 2021<\/em>
\n ; click <\/em>
\n
\n
\n here<\/u>
\n <\/em>
\n <\/a>
\n to submit trade information<\/em>\n <\/p>\n

LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm<\/u><\/a> advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation.<\/p>\n

Investors are encouraged to contact attorney Lesley F. Portnoy<\/u><\/a>,<\/u> to determine eligibility to participate in this action, by phone 310-692-8883 or email<\/u><\/a>, or click here<\/u><\/a> to join the case.<\/p>\n

It is alleged in this complaint that throughout the Class Period, AcelRx made materially misleading and false statements and\/or failed to disclose that: (1) AcelRx\u2019s disclosure controls and procedures with respect to its marketing of DSUVIA were deficient; (2) AcelRx had been making misleading or false claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays, as a result; (3) the foregoing conduct subjected AcelRx to increased regulatory enforcement and scrutiny; and (4) AcelRx\u2019s public statements were materially false and misleading at all relevant times, as a result.<\/p>\n

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 9, 2021.<\/p>\n

Please visit our website<\/u><\/a> to review more information and submit your transaction information.<\/p>\n

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm\u2019s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com<\/u><\/a>
310-692-8883
www.portnoylaw.com<\/p>\n

Attorney Advertising<\/p>\n<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Investors with losses are encouraged to contact the firm before August 9, 2021 ; click here to submit trade information LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that throughout the Class Period, AcelRx made materially misleading … <\/p>\n

Continue reading “AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-520937","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Investors with losses are encouraged to contact the firm before August 9, 2021 ; click here to submit trade information LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that throughout the Class Period, AcelRx made materially misleading … Continue reading "AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-30T23:26:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm\",\"datePublished\":\"2021-07-30T23:26:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/\"},\"wordCount\":295,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/\",\"name\":\"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=\",\"datePublished\":\"2021-07-30T23:26:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/","og_locale":"en_US","og_type":"article","og_title":"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Market Newsdesk","og_description":"Investors with losses are encouraged to contact the firm before August 9, 2021 ; click here to submit trade information LOS ANGELES, July 30, 2021 (GLOBE NEWSWIRE) — The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) investors that acquired shares between March 17, 2020 to February 12, 2021. Investors have until August 9, 2021 to seek an active role in this litigation. Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case. It is alleged in this complaint that throughout the Class Period, AcelRx made materially misleading … Continue reading \"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-30T23:26:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm","datePublished":"2021-07-30T23:26:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/"},"wordCount":295,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/","name":"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=","datePublished":"2021-07-30T23:26:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI5MDM3MyM0MzI0NjY2IzIxOTU1Mjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/acelrx-pharmaceuticals-inc-investors-last-days-to-participate-actively-in-the-class-action-lawsuit-portnoy-law-firm\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520937","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=520937"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/520937\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=520937"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=520937"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=520937"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}